BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35984205)

  • 41. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
    Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of Preoperative Ki67 and Serum CA15.3 Levels with Outcome in Early Breast Cancers a Multi Institutional Study.
    Rasmy A; Abozeed W; Elsamany S; Baiomy ME; Nashwa A; Amrallah A; Hasaan E; Alzahrani A; Faris M; Alsaleh K; AlFaraj A
    Asian Pac J Cancer Prev; 2016; 17(7):3595-600. PubMed ID: 27510014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients.
    Incoronato M; Mirabelli P; Catalano O; Aiello M; Parente C; Soricelli A; Nicolai E
    BMC Cancer; 2014 May; 14():356. PubMed ID: 24886519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    Rangel N; Fortunati N; Osella-Abate S; Annaratone L; Isella C; Catalano MG; Rinella L; Metovic J; Boldorini R; Balmativola D; Ferrando P; Marano F; Cassoni P; Sapino A; Castellano I
    BMC Cancer; 2018 Jul; 18(1):703. PubMed ID: 29970021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
    Li Y; Qin J; Wu J; Dai X; Xu J
    Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of serum exosomal miR-148a as a novel prognostic biomarker for breast cancer.
    Li D; Wang J; Ma LJ; Yang HB; Jing JF; Jia MM; Zhang XJ; Guo F; Gao JN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7303-7309. PubMed ID: 32706068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis.
    Qiao EQ; Yang HJ; Zhang XP
    J Zhejiang Univ Sci B; 2020 Jun; 21(6):495-508. PubMed ID: 32478495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
    Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential value of circulatory microRNA10b gene expression and its target E-cadherin as a prognostic and metastatic prediction marker for breast cancer.
    Dwedar FI; Shams-Eldin RS; Nayer Mohamed S; Mohammed AF; Gomaa SH
    J Clin Lab Anal; 2021 Aug; 35(8):e23887. PubMed ID: 34264524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
    Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
    Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
    BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
    Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
    Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
    El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
    Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.
    Chung L; Moore K; Phillips L; Boyle FM; Marsh DJ; Baxter RC
    Breast Cancer Res; 2014 Jun; 16(3):R63. PubMed ID: 24935269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pleiotrophin as a potential biomarker in breast cancer patients.
    Ma J; Kong Y; Nan H; Qu S; Fu X; Jiang L; Wang W; Guo H; Zhao S; He J; Nan K
    Clin Chim Acta; 2017 Mar; 466():6-12. PubMed ID: 28041942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.